Targeted therapies for adjuvant therapy - AIM with Immunotherapy - Immuno-Oncology Essentials

This topic has 1 reply, 2 voices, and was last updated November 3, 2017 at 2:07 am by Anonymous.

Viewing 2 posts - 1 through 2 (of 2 total)

Author

Posts
November 1, 2017 at 6:51 pm #4263
Anonymous
Can you please provide commentary about the new data on use of BRAF/MEK inhibitors in the adjvuvant setting? Do you expect the side effects to be similar to what is seen in the metastatic setting?
November 3, 2017 at 2:07 am #4276
Anonymous
Hi Lisa,
Krista Rubin gave an excellent overview of targeted therapy in the adjuvant setting (from the COMBI-AD Phase 3 trial) in the immunotherapy section above. In terms of practice change, this would call for BRAF testing in all Stage III patients which is not necessarily the standard approach for all practices. This is a very exciting time in melanoma!
Author

Posts

Viewing 2 posts - 1 through 2 (of 2 total)

You must be logged in to reply to this topic.

Copyright ©2022- - AIM with Immunotherapy. All rights reserved.